FTC sues largest drug middlemen for allegedly inflating insulin prices
Headline from ABC 12 Flint
The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies of artificially inflating insulin list prices that resulted in patients paying more for
ABC 12 Flint's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies of artificially inflating insulin list prices that resulted in patients paying more for
The enforcement action is part of an escalating conflict between the FTC and the three pharmacy benefit managers that together control about 80% of prescriptions filled in the US.
The FTC sued UnitedHealth Group's Optum unit, CVS Caremark and Cigna's Express Scripts for allegedly steering diabetes patients towards higher priced insulin.
The Federal Trade Commission on Friday filed lawsuits against three prescription drug benefit managers or PBMs over concerns the companies are artificially inflating the list price of insulin drugs.
The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged anticompetitive practices that boosted profits while “artificially” inflating the list price of insulin.
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
FTC sues largest drug middlemen for allegedly inflating insulin prices | Since Then
